Find The Best Stocks With Perfect Trade Setups In Minutes A Day

Stop wasting time looking for the right stocks.  Free training on how to find perfect stock trades that can move 300-1,500%.  Learn the # 1 key to successful stock investing and how to find success even If the market is crashing, rebounding… or just going sideways. (ad)

Do Not Delay - Click Here Now


The U.S. Surpassed 100,000 Coronavirus Deaths

Plus, another 2.1 million Americans applied for unemployment benefits last week, Trump is expected to sign an executive order to crack down on liability protections for social media platforms, and Abercrombie shares are down after the mall-staple reported a 34% drop in sales in the first quarter.

Stocks were higher to start Thursday with the Dow adding 67 points, or nearly 0.3%. The S&P 500 gained 0.4%, while the Nasdaq traded 0.45% higher.

Hey, do you want to be the next stock market millionaire? This free training lays it all out for you! Check it out here.

Another 2.1 million Americans applied for unemployment benefits last week, bringing the total amid the coronavirus pandemic to more than 40 million. But it’s not all bad news in this week’s jobs report, as it market the eighth straight week-over-week decline in new claims. Also good news, continuing claims fell to 21.05 million, down by 3.86 million from the week prior. “The data still point to a pretty significant loss of jobs but at least the numbers are moving in the right direction,” said Aneta Markowska, chief financial economist at Jefferies Group. “Even though initial claims are still very elevated, the fact that continuing claims are declining means businesses are actually bringing a lot of workers back in and that is more than offsetting the new filings.”

The U.S. reached a grim milestone: 100,000 dead from the coronavirus, just 126 days since the first case and 87 days since the CDC announced the first fatality on February 29. In treatment news, Roche is teaming up with Gilead Sciences on a late-stage trial of a two-drug combination of Roche’s immune suppressor Actemra and Gilead’s antiviral remdesivir, with the results of the combination treatment compared to those from patients who just receive remdesivir and a placebo. The companies will begin enrolling as many as 450 patients in the U.S., Canada, and Europe in June. Roche’s Actemra is a drug used to counter harmful inflammation and is often used to treat rheumatoid arthritis. Other drugmakers experimenting with anti-inflammatory treatments for COVID-19 include AstraZeneca, GlaxoSmithKline, Regeneron Pharmaceuticals, and Sanofi.

Chinese lawmakers defied the U.S. by approving the proposal to impose a new national security law for Hong Kong, paving the way for the legislation to be finalized and implemented in the city. Ahead of the decision, protests reignited in Hong Kong, with large crowds out in force in the territory following last Friday’s introduction of the legislation. While details of the law are still scarce, it will now more to the Standing Committee to work out the implementation details which are expected to target secession, subversion of state power, terrorism activities, and foreign interference. The U.S. said yesterday that it can no longer certify Hong Kong’s autonomy, a move that could trigger sanctions on Chinese officials or revoking the city’s special trading status.

President Donald Trump is expected to sign an executive order today that will crack down on liability protections for online social media platforms including Twitter, Facebook, and Google, just days after Twitter began fact-checking some of Trump’s tweets. The order will push the FCC to write rules on when and how platforms can remove content from their platforms and still maintain liability protection granted to them under Section 230 of the Communications Decency Act. More specifically, Trump wants the government to now define what it means for social media companies to act in bad faith when dealing with questionable content, opening up such platforms to lawsuits. Meanwhile, Twitter CEO Jack Dorsey stands by the company’s decision to fact-check two of Trump’s tweets. “This does not make us an ‘arbiter of truth,’” Dorsey tweeted. “Our intention is to connect the dots of conflicting statements and show the information in dispute so people can judge for themselves. More transparency from us is critical so folks can clearly see the why behind our actions.”

And Abercrombie & Fitch shares are down nearly -5% this morning after the clothing retailer reported that its sales tanked 34% during the first quarter due to store closings amid the coronavirus crisis. The company reported an adjusted loss of $3.29 per share on revenue of $485.4 million, down from $734 million in the same quarter last year. Sales at its namesake Abercrombie brand were down 30%, while its Hollister brand sales were down 36%. CEO Fran Horowitz said that around half of Abercrombie’s global store base, or 409 shops, are now back open for business, and said that in the U.S., “we are encouraged by recent results, with customers returning to stores at an even quicker pace than in China.” Horowitz added, “While this year is a lost one across the space from an earnings perspective, we do see improved underlying brand health.”

Stocks We’re Watching

StoneCo Ltd (NASDAQ: STNE): StoneCo shares jumped as much as 29% yesterday after the Brazilian payments processor reported better-than-expected Q1 earnings. StoneCo’s e-commerce volume in May has already returned to 87% of what was seen before the coronavirus pandemic, and Susquehanna analyst James Friedman says volume may be growing to nearly 80% year-over-year. “A combination of their quick pivot to enabling e-commerce for their merchants—coupled with a footprint in less affected regions—is enabling a faster than expected recovery,” Friedman wrote in a note where he raised his price target on the stock from $28 to $34.

By the way, if you liked this article, you'll LOVE this Meaty free training I just published on the top 3 questions and challenges every investor faces AND how to overcome them. It's titled "10k into $2.4 Million in 18 months" and you can grab it for free here

There are risks inherent in all investments, which may make such investments unsuitable for certain persons. These include, for example, economic, political, currency exchange, rate fluctuations, and limited availability of information on international securities. You may lose all of your money trading and investing. Do NOT enter any trade without fully understanding the worst-case scenarios of that trade. And do NOT trade with money you cannot afford to lose. Past performance of an investment is not necessarily indicative of its future results. No assurance can be given that any implied recommendation will be profitable or will not be subject to losses. Information provided by the Company is not investment advice. The Company is not a registered investment adviser, stock broker, or brokerage. You agree that the Company does not represent, warrant, or take responsibility that any account will or is likely to achieve profit or losses similar to those shown. Examples published by the Company are selected for illustrative purposes only. They are not typical and do not represent the typical results of all stocks within the Companys software or its individual scans and searches. No independent party has audited any hypothetical performance contained at this Web site, nor has any independent party undertaken to confirm that they reflect the trading method under the assumptions or conditions specified.

FREE TRADING WEBINAR - TRADERSPRO PRESENTS: Starting With Only $10,000 Retire With $2.4 Million? Click Here Now

Join Us Now